Duramed Pharmaceuticals, an innovator in womens healthcare pharmaceutical products, focuses its product development and marketing activities on products for women. The Futures Golf Tour is the official developmental tour of the Ladies Professional Golf Association (LPGA) and serves as an opportunity for more than 300 of the worlds best young women professional golfers from 27 countries to prove their game and earn their way on to the LPGA Tour, the leading women's professional golf tour in the world.
We are proud to be the title sponsor of the Duramed Futures Tour, said Bruce L. Downey, Barrs chairman and CEO. The Duramed Futures Tour celebrates the talents and dreams of tomorrows female golf stars. Duramed is committed to providing women with pharmaceutical products that offer them reproductive and hormonal options that complement their active lifestyles. This partnership brings together two powerful forces committed to women, and will enable us to highlight that commitment, as well as to reinforce our message of the importance of female healthcare.
Duramed is an ideal partner for the Futures Tour because of the company's history of commitment to women and womens health, said Zayra F. Calderon, president and CEO of the Duramed Futures Tour. This partnership will greatly impact the landscape for womens golf by providing more opportunity for growth of the sport. I am delighted with Duramed's pledge to support local tournament markets and they will be a valuable ally in helping raise funds for our charities.
Calderon continued, Our agreement with Duramed comes on the heels of one of the most successful seasons in the Tour's 25-year history. Duramed will enhance our brand awareness and increase recognition as the world's premier womens developmental tour. It solidifies our value proposition to showcase the most talented, exciting, young, dynamic golfers in the world and provide them direct access to play on the LPGA Tour.
Under this three-year sponsorship, Duramed will become the national title sponsor of the Futures Tour, will establish a player program to recognize those players who receive exempt status on the LPGA each year and will have the naming rights to the Player of the Year award. Duramed will also have access to 18 different tournament markets throughout the United States, as well as significant presence at each tournament venue.